IRCT2012091710862N1已完成未知
Comparison of Iron Chelation Effects of Deferoxamine, Deferasirox, and Combination of Deferoxamine and Deferiprone in Thalassemia Maior
Tehran University of Medical Sciences Vice chancellor for research0 个研究点目标入组 108 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 108
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 10 years 至 40 years（—）
- 性别
- All
入选标准
- •transfusion dependent thalassemia with age over 10 years;cardiac iron load on MRI T2 *
- •Exclusion criteria : severe hepatic disorder; renal disease; history of neutropenia; history of adverse reactions to any of chelators in the past; failure to perform MRI T2 * due to causes such as pacemakers; pregnancy; fear of closed environment
排除标准
- 未提供
研究者
相似试验
已完成
Unknown
Deferoxamine to treat Iron Overload in patients on Dialysis: effect on bone, myocardial and liverRBR-3rnskcjHospital das Clinicas da Universidade de Sao Paulo
已完成
4 期
Efficacy and Safety of Oral Deferasirox (20 mg/kg/d) in Pts 3 to 6 Months After Allogeneic Hematopoietic Cell Transplantation Who Present With Iron OverloadIron OverloadNCT00654589Novartis Pharmaceuticals75
已完成
4 期
Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndrome and Transfusion-dependent Iron OverloadMyelodysplastic SyndromesTransfusion Dependent Iron OverloadNCT00481143Novartis Pharmaceuticals63
已完成
不适用
Iron chelation with Deferasirox under conditioning therapy prior to allogenic stem cell transplantatioE83.1Disorders of iron metabolismDRKS00015498niversitätsklinikum Hamburg-Eppendorf, Klinik für Stammzelltransplantation25
进行中（未招募）
1 期
conservative iron chelation by deferiprone for amyotrophic lateral sclerosisDe novo Amyotrophic Lateral Sclerosis patientsEUCTR2017-003763-35-FRcentre hospitalier universitaire de Lille240